Shares of Lupin are set to be in focus after it received US FDA approval for its generic Loteprednol Etabonate Ophthalmic Gel, granting it 180 days of exclusivity in the $29 million US market. This follows Lupin’s US launch of Prucalopride tablets for chronic constipation, targeting a market worth $184 million. Both drugs will be manufactured in India.